checkAd
    Startseite > Aktien > RenovoRx > Nachrichten
    RenovoRx Aktie
    1,4200
     
    USD
    +2,90 %
    +0,0400 USD
    Letzter Kurs 22:30:00 Nasdaq
    1,4200
     
    USD
    200 STK
    Geldkurs 22:02:00
    1,4600
     
    USD
    500 STK
    Briefkurs 22:02:00
    ISIN: US75989R1077 · WKN: A3CYE8 · SYM: RNXT · USA

    Neueste Nachrichten

    RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024
    14.05.24 · Business Wire (engl.) · RenovoRx
    RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024
    02.05.24 · Business Wire (engl.) · RenovoRx
    RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement
    18.04.24 · Business Wire (engl.) · RenovoRx
    RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
    16.04.24 · Business Wire (engl.) · RenovoRx
    RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026
    15.04.24 · Business Wire (engl.) · RenovoRx
    RenovoRx Announces $11.1 Million at Market Private Placement
    08.04.24 · Business Wire (engl.) · RenovoRx
    RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024
    05.04.24 · Business Wire (engl.) · RenovoRx
    RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024
    12.03.24 · Business Wire (engl.) · RenovoRx
    RenovoRx Highlights Key Leadership Promotions
    08.03.24 · Business Wire (engl.) · RenovoRx
    RenovoRx CEO Issues Letter to Shareholders
    06.02.24 · Business Wire (engl.) · RenovoRx
    RenovoRx Closes $6.1 Million Private Placement
    29.01.24 · Business Wire (engl.) · RenovoRx
    RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer
    21.12.23 · Business Wire (engl.) · RenovoRx